Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-p53 TCR-Engineered Lymphocytes for Metastatic Cancer
NCT00393029Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2006
- Primary completion
- Nov 2008
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of autologous p53-specific T cells in metastatic cancer, melanoma, renal cell carcinoma (RCC), sponsored by National Cancer Institute. Started Oct 2006; status: completed.
02
Drugs
autologous p53-specific T cells
03
Conditions
metastatic cancermelanomarenal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00393029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00393029.